Evidence map›Paper›PMID 32609743›Full record

ArticlePloS one2020

Systemic evaluation and localization of resistin expression in normal human tissues by a newly developed monoclonal antibody.

Qing Lin, Shari A Price, John T Skinner, Bin Hu, Chunling Fan, Kazuyo Yamaji-Kegan, Roger A Johns

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. An overview of immunohistochemistry: Evidence and personal experience.The Journal of international medical research · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Qing LinDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Shari A PriceCharles River Laboratories, Inc., Frederick, MD, United States of America.
John T SkinnerDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Bin HuDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Chunling FanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Kazuyo Yamaji-KeganDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Roger A JohnsDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0001-9232-2434
Johns Hopkins University · USCharles River Laboratories (United States) · US

Funding

Targeting resitin and RELM-beta to treat pulmonary hypertensionUH3HL123827 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JOHNS, ROGER A · 2016 to 2018
$4.9M
Targeting resitin and RELM-beta to treat pulmonary hypertensionUH2HL123827 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JOHNS, ROGER A · 2014 to 2015
$3.1M
Insulin Receptor Substrate Signaling in Pulmonary HypertensionR01HL135022 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI KEEGAN, ACHSAH D. · 2018 to 2022
$2.0M
DAMP Signaling Mediates HIMF-induced Pulmonary HypertensionR01HL138497 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JOHNS, ROGER A · 2018 to 2021
$1.8M
Targeting resitin and RELM-beta to treat pulmonary hypertensionP50HL107182 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JOHNS, ROGER A · 2011 to 2012
$983k
NHLBI NIH HHS P50 HL107182NHLBI NIH HHS R01 HL135022NHLBI NIH HHS R01 HL138497NHLBI NIH HHS UH2 HL123827NHLBI NIH HHS UH3 HL123827
6 · The paper itself

Abstract

Resistin and resistin-like molecules are pleiotropic cytokines that are involved in inflammatory diseases. Our previous work suggested that resistin has the potential to be used as a biomarker and therapeutic target for human pulmonary arterial hypertension. However, data are limited on the distribution of resistin in healthy human organs. In this study, we used our newly developed anti-human resistin (hResistin) antibody to immunohistochemically detect the expression, localization, and intracellular/extracellular compartmentalization of hResistin in a full human tissue panel from healthy individuals. The potential cross reactivity of this monoclonal anti-hResistin IgG1 with normal human tissues also was verified. Results showed that hResistin is broadly distributed and principally localized in the cytoplasmic granules of macrophages scattered in the interstitium of most human tissues. Bone marrow hematopoietic precursor cells also exhibited hResistin signals in their cytoplasmic granules. Additionally, hResistin labeling was observed in the cytoplasm of nervous system cells. Notably, the cytokine activity of hResistin was illustrated by positively stained extracellular material in most human tissues. These data indicate that our generated antibody binds to the secreted hResistin and support its potential use for immunotherapy to reduce circulating hResistin levels in human disease. Our findings comprehensively document the basal expression patterns of hResistin protein in normal human tissues, suggest a critical role of this cytokine in normal and pathophysiologic inflammatory processes, and offer key insights for using our antibody in future pharmacokinetic studies and immunotherapeutic strategies.

Indexed as

Gene Expression RegulationAntibodies, MonoclonalExtracellular SpaceHEK293 CellsHumansImmunohistochemistryIntracellular SpaceOrgan SpecificityProtein TransportResistinAntibodies, MonoclonalResistin

Identifiers

PMID32609743
PMCPMC7329134
OpenAlexW3039933522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.